Sign in
Taking people in United StatesPhase 2/3

Linsitinib continued in adults with active thyroid eye disease

Tests linsitinib in adults with thyroid eye disease who took part in an earlier study.

Key facts

Who runs it
Sling Therapeutics, Inc.
Where
Miami and Morgantown, United StatesSee the 2 sites
Trial code
Registry title
Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
Status
Recruiting
Phase
Phase 2/3
People taking part
75 people, planned
Started
11 Oct 2023
Planned end
Jun 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • linsitinib
Record updated
25 February 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 5 criteriaShow less

Who can take part

  • Subject who completed the 24-week double-mask period of VGN-TED-301 and are proptosis non-responders (< 2 mm reduction in proptosis in the study eye) at Week 24 of VGN-TED-301 study or proptosis responders at Week 24 who relapse during the Follow-Up period of VGN-TED-301
  • Subject has not received any treatment for TED since Week 24 of VGN-TED-301
  • Subjects must be euthyroid with the participant's baseline disease under control or have mild hypo- or hyperthyroidism (defined as free thyroxine [FT4] and free triiodothyronine levels [FT3] <50% above or below the normal limits) at Baseline. Every effort should be made to correct mild hypo- or hyperthyroidism promptly and maintain the euthyroid state for the duration of the clinical trial
  • Does not require immediate ophthalmic surgery, radiotherapy to orbits or other ophthalmological intervention at the time of Baseline and is not planning for any such treatment during the course of the study

Who cannot take part

  • The exclusion criteria of protocol VGN-TED-301 also apply to this extension study

This trial is currently available in United States.

  • Bascom Palmer Eye InstituteMiami, United StatesContact: Jennifer GomezTaking people
  • West Virginia University Eye InstituteMorgantown, United StatesContact: Athena EcholsTaking people

About the trial

What the trial wants to find out

The overall study objective is to continue to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of linsitinib in subjects who were enrolled in the prior VGN-TED-301 through Week 24. These subjects include VGN-TED-301 Week 24 proptosis non-responders or subjects who relapse during the Follow-Up Period of VGN-TED-301.

The 2 groups in the trial

  • Low DoseExisting treatment, for comparison

    Active Arm Low Dose Linsitinib

    Treatment: linsitinib

  • High DoseExisting treatment, for comparison

    Active Arm High Dose Linsitinib

    Treatment: linsitinib

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Multicenter, Extension Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
Plain-language title
Linsitinib continued in adults with active thyroid eye diseaseGenerated from the registry record. The registry title is the official one.
Record updated
25 February 2025